Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …

ErbB3 is an important regulator of tumorigenesis and is implicated in development of
resistance to several currently used oncology drugs. We have identified ErbB3 inhibitors …

In the last 3-5 years strong evidence has been gathered demonstrating ErbB3 as a key node
for the progression of several cancer types. From the mechanistic standpoint the intracellular …

Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal
antibody shuts down receptor signaling and has potent antitumor activity even in tumors that …

Cancer progression depends on stepwise accumulation of oncogenic mutations and a
select group of growth factors essential for tumor growth, metastasis and angiogenesis …

ErbB-2 is an orphan receptor that belongs to a family of tyrosine kinase receptors for either
epidermal growth factor (EGF) or Neu differentiation factor (NDF/neuregulin). Because …

The overexpression and aberrant function of members of the erbB family of receptors,
particularly erbB1 (also known as epidermal growth factor receptor), and its ligands in many …

ErbB2 is a prognostic factor and target of therapy for many carcinomas. In contrast with the
other ErbB receptors, ErbB2 lacks a soluble direct ligand, but it is the preferred co-receptor …

ErbB1 and ErbB2 constitute validated target antigens for tumor therapy—as documented by
the approval of antibodies and tyrosine kinase inhibitors (TKIs) against both antigens …

Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb)
family plays a crucial part in the development and evolution of cancer. Inhibiting the …